Compare Msci Inc (MSCI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Novartis AG — how do they compare? Msci Inc trades at $562.19 (market cap $40.38B), while Novartis AG trades at $142.74 (market cap $274.00B). The key difference: Novartis AG is far larger — about 6.8× Msci Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Novartis AG for 82 Days on average.
| MSCI | NVS | |
|---|---|---|
Market Cap | $40.38B | $274.00B |
Volume | 414,140 | 1,852,137 |
Sector | Financials | Health |
52-Week High | $643.83 | $168.62 |
52-Week Low | $511.84 | $121.80 |
Typical Hold Time | 82 Days | 82 Days |
Enterprise Value | $46.54B | $315.32B |
Dividend Yield | 1.48% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $555.38, up 0.08% with neutral technical signals. The company demonstrates strong fundamentals with 2025 revenue of $3.13B and net income margin of 40.73%. Recent Q2 2026 earnings slightly missed expectations at $4.94 EPS versus $4.99 expected, though Q1 and Q4 2025 beat estimates. Analyst consensus remains strongly bullish with 74% buy ratings and $701.71 price target, representing 26% upside potential. The stock shows consistent revenue growth from $2.2B in 2022 to $3.1B in 2025.
MSCI presents a compelling investment case with premium valuation (P/E 30.37) justified by strong profitability and market leadership. Key risks include high debt levels ($4.51B long-term debt) and competitive pressures in financial data services. The upcoming Q3 2026 earnings report on October 20, 2026, will be crucial for validating growth trajectory. Institutional sentiment remains positive given the company's recurring revenue model and expansion into climate risk analytics through the First Street acquisition.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
